Intravenous chlorpromazine for the treatment of insomnia in end-stage cancer patients with difficulty in oral administration

Intravenous chlorpromazine for the treatment of insomnia in end-stage cancer patients with difficulty in oral administration - Intravenous chlorpromazine for the treatment of insomnia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029365

Enrollment

Registered

2017-10-01

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sleep disturbance

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Study subjects were 30 end-stage cancer patients with difficulty in oral administration from whom the informed consent for intravenous chlorpromazine was obtained.

Exclusion criteria

Exclusion criteria: We focused on only primary insomnia excluding secondary insomnia attributed to delirium or medications. The study excluded psychiatric disorder patients with difficulty in communication such as dementia.

Design outcomes

Primary

Measure	Time frame
Primary endpoint in this study was sleep quality based on St. Marys Hospital Sleep Questionnaire 3 days after the chlorpromazine treatment as a chlorpromazine efficacy index.	—

Countries

Japan

Contacts

Public ContactHideaki Hasuo

Kansai Medical University Department of Psychosomatic Medicine

hasuohid@hirakata.kmu.ac.jp072-804-0101

Outcome results